Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

INBX

Inhibrx Inc

May 03 • 04:00PM ET

34.15

Dollar change +0.14
Percentage change 0.41	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO LABU VTWO SCHA IWN VHT

Index	RUT	P/E	-	EPS (ttm)	-5.03	Insider Own	24.89%	Shs Outstand	47.37M	Perf Week	0.26%
Market Cap	1.62B	Forward P/E	-	EPS next Y	-4.30	Insider Trans	0.00%	Shs Float	35.60M	Perf Month	-1.44%
Income	-241.36M	PEG	-	EPS next Q	-1.01	Inst Own	80.38%	Short Float	6.18%	Perf Quarter	-8.37%
Sales	1.80M	P/S	899.09	EPS this Y	19.43%	Inst Trans	8.06%	Short Ratio	4.75	Perf Half Y	116.28%
Book/sh	0.92	P/B	37.19	EPS next Y	-4.24%	ROA	-80.62%	Short Interest	2.20M	Perf Year	26.53%
Cash/sh	5.86	P/C	5.82	EPS next 5Y	-	ROE	-475.31%	52W Range	14.31 - 39.79	Perf YTD	-10.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-43.13%	ROI	-95.94%	52W High	-14.17%	Beta	2.88
Dividend TTM	-	Quick Ratio	5.25	Sales past 5Y	-16.05%	Gross Margin	-14.17%	52W Low	138.73%	ATR (14)	0.49
Dividend Ex-Date	-	Current Ratio	5.25	EPS Y/Y TTM	-39.09%	Oper. Margin	-12178.94%	RSI (14)	41.15	Volatility	1.62% 1.28%
Employees	172	Debt/Eq	4.83	Sales Y/Y TTM	-17.36%	Profit Margin	-13408.94%	Recom	3.00	Target Price	35.00
Option/Short	Yes / Yes	LT Debt/Eq	4.78	EPS Q/Q	-83.20%	Payout	-	Rel Volume	0.53	Prev Close	34.01
Sales Surprise	3168.00%	EPS Surprise	-66.88%	Sales Q/Q	496.35%	Earnings	Feb 28 BMO	Avg Volume	463.12K	Price	34.15
SMA20	-0.95%	SMA50	-3.14%	SMA200	25.44%	Trades		Volume	246,595	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-23-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Mar-16-22	Initiated	SMBC Nikko	Outperform	$40
Sep-21-21	Initiated	JMP Securities	Mkt Outperform	$46
Apr-26-21	Resumed	Credit Suisse	Outperform	$44
Sep-14-20	Initiated	Evercore ISI	Outperform	$30
Sep-14-20	Initiated	Credit Suisse	Outperform	$26

Feb-28-24 10:25AM	Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.47%
09:15AM	Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results (PR Newswire)
Jan-29-24 11:53PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, KAMN, BATL (PR Newswire)
Jan-26-24 12:12PM	Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm (PR Newswire)
Jan-24-24 09:46AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, MDC, ANSS, HMST (GlobeNewswire)
05:58AM	Loading…
05:58AM	Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-23-24 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal) +8.91%
04:42PM	These Stocks Moved the Most Today: United, 3M, Verizon, Plug Power, Johnson & Johnson, GE, and More (Barrons.com)
04:02PM	Inhibrx Soared 176% Over Two Months Now, Sanofi Is Buying It (Investor's Business Daily)
02:45PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates INBX, SP, WAVD, CATC (PR Newswire)
02:30PM	Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi (Zacks)
01:23PM	These Stocks Are Moving the Most Today: United, 3M, Verizon, Plug Power, Johnson & Johnson, GE, and More (Barrons.com)
11:25AM	Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline (Investopedia)
09:40AM	Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx (Investor's Business Daily)
06:02AM	Sanofi to buy Inhibrx in deal worth up to $2.2B (BioPharma Dive)
05:39AM	Loading…
05:39AM	Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion (The Wall Street Journal)
05:27AM	Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs (FierceBiotech.com)
01:32AM	France's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal (Reuters)
01:29AM	UPDATE 3-France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal (Reuters)
01:12AM	France's Sanofi to buy U.S. drugs project INBRX-101 for around $2.2 bln (Reuters)
01:00AM	Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B (PR Newswire)
Nov-09-23 04:00PM	Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
Nov-02-23 09:15AM	Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma (PR Newswire)
Oct-18-23 04:00PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Sep-19-23 04:00PM	Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada (PR Newswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
Aug-29-23 09:00AM	Inhibrx Announces $200 Million Private Placement Financing (PR Newswire) +13.33%
Aug-07-23 04:00PM	Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire) -6.21%
May-30-23 09:00AM	Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
May-08-23 06:05PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (PR Newswire)
May-03-23 09:58PM	Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength? (Zacks) +9.89%
02:18PM	Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating (Investor's Business Daily)
Apr-26-23 09:00AM	Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials (PR Newswire)
Mar-23-23 07:25AM	The past year for Inhibrx (NASDAQ:INBX) investors has not been profitable (Simply Wall St.)
Mar-06-23 05:35PM	Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results (PR Newswire)
Jan-30-23 07:33AM	Should You Hold Inhibrx (INBX)? (Insider Monkey) -7.41%
Jan-04-23 09:00AM	NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates (PR Newswire)
Nov-18-22 04:05PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
10:16AM	Inhibrx (INBX) Down on Updated Data From Bone Cancer Study (Zacks)
Nov-16-22 10:42AM	Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate (Benzinga)
09:00AM	Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
Nov-09-22 06:08AM	Inhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-07-22 05:55PM	Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.04%
04:05PM	Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
Oct-20-22 04:05PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-13-22 06:56AM	Investors in Inhibrx (NASDAQ:INBX) have unfortunately lost 18% over the last year (Simply Wall St.) +6.46%
Oct-04-22 09:28AM	Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge (Benzinga) +47.47%
08:00AM	Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study (PR Newswire)
Oct-03-22 04:30PM	Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire) +12.42%
Aug-15-22 04:05PM	European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma (PR Newswire)
Aug-08-22 07:25PM	Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.27%
05:19PM	Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
Jun-30-22 09:00AM	Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance (PR Newswire) -5.34%
May-19-22 04:05PM	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting (PR Newswire) -5.08%
May-16-22 12:32PM	Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder (Benzinga) -18.95%
09:00AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
May-09-22 06:35PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.23%
05:25PM	Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights (PR Newswire)
May-05-22 05:15PM	KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.76%
06:18AM	The 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25% (Simply Wall St.)
May-03-22 06:32AM	Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock? (Zacks)
Apr-25-22 09:00AM	Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 (PR Newswire)
Apr-05-22 04:30PM	Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting (PR Newswire) -5.50%
Mar-24-22 04:05PM	Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting (PR Newswire)
Mar-03-22 09:15AM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
Feb-28-22 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
Feb-22-22 09:00AM	Inhibrx Announces Amended Loan Agreement with Oxford (PR Newswire)
Jan-05-22 07:46AM	Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors (Benzinga) -5.83%
Jan-04-22 04:05PM	Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data (PR Newswire) -8.62%
Dec-20-21 08:50AM	Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price Strength (Zacks)
Dec-01-21 04:05PM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma (PR Newswire)
Nov-25-21 09:08AM	Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval (Zacks)
Nov-24-21 10:31AM	Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension (Zacks) +5.48%
Nov-23-21 10:00AM	Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should Know (Zacks)
Nov-10-21 07:47AM	Inhibrx (NASDAQ:INBX) pulls back 3.4% this week, but still delivers shareholders impressive 139% return over 1 year (Simply Wall St.)
Nov-09-21 06:45PM	Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights (PR Newswire)
Nov-05-21 03:00PM	Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-21 08:00AM	Inhibrx Announces Presentations at SITC 2021 (PR Newswire)
Nov-01-21 05:51PM	Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences (PR Newswire) +14.51%
Oct-28-21 08:30AM	Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-12-21 12:22PM	30 Stocks Moving In Tuesday's Mid-Day Session (Benzinga) +21.98%
12:11PM	Here's Why Inhibrx Stock Is on the Move Today (Motley Fool)
07:30AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing (PR Newswire)
Oct-11-21 04:05PM	Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency (PR Newswire)
Sep-13-21 04:30PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire)
Aug-12-21 01:37AM	The Inhibrx, Inc. (NASDAQ:INBX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts (Simply Wall St.) -6.10%
Aug-09-21 04:38PM	Inhibrx Reports Second Quarter 2021 Financial Results (PR Newswire)
Jun-22-21 06:49AM	Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford (Benzinga)
Jun-21-21 04:05PM	Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford (PR Newswire)
May-17-21 04:05PM	Inhibrx Announces Participation in Upcoming Investor Conferences (PR Newswire)
May-13-21 04:10PM	Inhibrx Reports First Quarter 2021 Financial Results (PR Newswire)
Mar-14-21 03:21AM	Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish (SmarterAnalyst)
Mar-12-21 09:00AM	Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist (PR Newswire) -6.37%
Feb-01-21 05:42PM	Inhibrx Announces Participation in Upcoming Investor Conference (PR Newswire) +7.32%
Jan-13-21 09:00AM	Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients (PR Newswire) +13.16%
Dec-10-20 06:24PM	Is INBX A Good Stock To Buy Now? (Insider Monkey) +9.32%

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm's pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Aug 28 '23	Buy	19.35	511,627	9,899,982	511,627	Aug 30 08:44 PM

Open in Screener

BDSX

Biodesix Inc

May 03 • 04:00PM ET

1.40

Dollar change +0.09
Percentage change 6.87	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI IWC

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	69.90%	Shs Outstand	96.24M	Perf Week	13.36%
Market Cap	160.37M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	-0.14%	Shs Float	34.48M	Perf Month	-7.28%
Income	-52.15M	PEG	-	EPS next Q	-0.14	Inst Own	11.14%	Short Float	0.91%	Perf Quarter	-33.96%
Sales	49.09M	P/S	3.27	EPS this Y	43.47%	Inst Trans	16.31%	Short Ratio	2.29	Perf Half Y	0.72%
Book/sh	0.05	P/B	29.42	EPS next Y	23.52%	ROA	-54.32%	Short Interest	0.32M	Perf Year	-15.15%
Cash/sh	0.23	P/C	6.08	EPS next 5Y	-	ROE	-414.09%	52W Range	1.03 - 2.21	Perf YTD	-23.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.42%	ROI	-80.26%	52W High	-36.65%	Beta	1.14
Dividend TTM	-	Quick Ratio	1.15	Sales past 5Y	24.79%	Gross Margin	73.50%	52W Low	35.92%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.19	EPS Y/Y TTM	59.45%	Oper. Margin	-84.13%	RSI (14)	59.03	Volatility	5.13% 6.50%
Employees	217	Debt/Eq	13.25	Sales Y/Y TTM	28.46%	Profit Margin	-106.23%	Recom	1.00	Target Price	3.25
Option/Short	Yes / Yes	LT Debt/Eq	13.19	EPS Q/Q	71.86%	Payout	-	Rel Volume	1.10	Prev Close	1.31
Sales Surprise	-6.07%	EPS Surprise	8.34%	Sales Q/Q	52.66%	Earnings	May 08 AMC	Avg Volume	137.63K	Price	1.40
SMA20	10.52%	SMA50	0.53%	SMA200	-9.44%	Trades		Volume	151,009	Change	6.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	Lake Street	Buy	$3
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21 → $11
Nov-23-20	Initiated	William Blair	Outperform
Nov-23-20	Initiated	Morgan Stanley	Overweight	$20
Nov-23-20	Initiated	Canaccord Genuity	Buy	$26
Nov-23-20	Initiated	BTIG Research	Buy	$22

Apr-24-24 06:00AM	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-09-24 05:00PM	Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting (Business Wire) -9.93%
Apr-05-24 07:17AM	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement (Business Wire) -7.28%
Mar-25-24 06:00AM	Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center (Business Wire)
Mar-04-24 09:04AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript (Insider Monkey)
10:40PM	Loading…
Mar-01-24 10:40PM	Q4 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
06:31AM	Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin (GuruFocus.com)
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights (Business Wire)
Feb-26-24 06:00AM	Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-16-24 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 (Business Wire) -5.73%
Feb-13-24 03:00AM	Biodesix Inc CEO Scott Hutton Sells 64,390 Shares (GuruFocus.com)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Nov-14-23 06:00AM	Biodesix Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method (Business Wire)
Nov-09-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in November (Business Wire) -6.39%
Nov-07-23 04:01PM	Biodesix Announces Third Quarter 2023 Results and Highlights (Business Wire)
06:00AM	Loading…
Oct-24-23 06:00AM	Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire) -5.00%
Oct-03-23 06:00AM	Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting (Business Wire)
Sep-07-23 06:00AM	Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer (Business Wire)
Sep-05-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -11.76%
Aug-22-23 06:00AM	Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer (Business Wire)
Aug-09-23 10:25AM	Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript (Insider Monkey) -15.62%
Aug-08-23 08:38AM	Q2 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2023 Results and Highlights (Business Wire)
Aug-01-23 06:00AM	Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +20.17%
Jul-26-23 07:58AM	Biodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year ago (Simply Wall St.)
Jul-24-23 06:00AM	Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023 (Business Wire)
Jul-12-23 06:00AM	Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules (Business Wire)
Jul-06-23 09:11AM	Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services (Business Wire)
Jun-27-23 06:00AM	Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier (Business Wire) -5.83%
06:00AM	Loading…
Jun-01-23 06:00AM	Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting (Business Wire)
May-31-23 06:00AM	Biodesix to Participate in William Blairs 43rd Annual Growth Stock Conference (Business Wire)
May-28-23 08:09AM	Jack Schuler Spends US$65k On Biodesix Stock \ (Simply Wall St.)
May-25-23 06:00AM	Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing (Business Wire) +5.30%
May-24-23 06:00AM	Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors (Business Wire) +12.68%
May-18-23 07:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference (Business Wire) -5.79%
May-12-23 11:10AM	Q1 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents) -12.28%
May-11-23 05:25PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2023 Results and Highlights (Business Wire)
May-09-23 06:15PM	Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-27-23 06:00AM	Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-12-23 06:53AM	Insiders of Biodesix, Inc. (NASDAQ:BDSX) must be frustrated after market cap dropped US$16m since recent purchases (Simply Wall St.)
Mar-15-23 09:31AM	Bullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last year (Simply Wall St.) +15.24%
Mar-08-23 07:14AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.06%
Mar-06-23 07:25AM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -10.00%
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights (Business Wire)
Feb-28-23 06:00AM	Biodesix to Participate at Cowens 43rd Annual Healthcare Conference (Business Wire)
Feb-21-23 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 (Business Wire)
Feb-16-23 06:27AM	Even after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past year (Simply Wall St.) +5.72%
Dec-19-22 06:00AM	Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test (Business Wire) +5.88%
Dec-16-22 04:01PM	Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors (Business Wire)
Dec-12-22 06:00AM	Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine (Business Wire) +8.57%
Nov-21-22 04:01PM	Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) -7.14%
Nov-17-22 12:26AM	Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock (Business Wire) +23.48%
Nov-16-22 04:05PM	Biodesix Announces Proposed Public Offering of Common Stock (Business Wire) +8.49%
04:01PM	Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million (Business Wire)
Nov-10-22 09:00AM	Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire)
Nov-09-22 05:33AM	Biodesix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -6.42%
Nov-03-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Third Quarter 2022 Results and Highlights (Business Wire)
Oct-20-22 06:00AM	Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-17-22 05:05PM	Boulder's Biodesix snags $20M contract, plans move to larger space in Louisville (American City Business Journals)
06:00AM	Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions (Business Wire)
Oct-12-22 06:00AM	Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs (Business Wire) -7.09%
Oct-11-22 06:00AM	Biodesix Announces Preliminary Revenue for Third Quarter 2022 (Business Wire)
Sep-06-22 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -6.56%
Aug-09-22 06:00AM	Biodesix Named a Top 100 Healthcare Technology Company of 2022 (Business Wire) -13.62%
Aug-06-22 04:30AM	Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Second Quarter 2022 Results and Highlights (Business Wire)
Aug-03-22 06:00AM	Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference (Business Wire) +5.34%
Jul-30-22 10:44AM	Biodesix, Inc. (NASDAQ:BDSX) insiders placed bullish bets worth US$21m in the last 12 months (Simply Wall St.)
Jul-20-22 06:00AM	Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors (Business Wire)
Jul-19-22 06:00AM	Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022 (Business Wire)
Jun-22-22 09:19AM	Sotera Health Company (SHC) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
Jun-15-22 10:11AM	Investors in Biodesix (NASDAQ:BDSX) have unfortunately lost 90% over the last year (Simply Wall St.)
Jun-07-22 06:00AM	Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test (Business Wire) +16.23%
Jun-03-22 06:00AM	Biodesix Announces Research Agreement with Top US Cancer Center (Business Wire)
Jun-01-22 06:00AM	Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference (Business Wire) -6.76%
May-17-22 06:00AM	Biodesix to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-12-22 06:00AM	Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference (Business Wire) +6.29%
May-11-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -15.41%
06:00AM	Biodesix Announces First Quarter 2022 Results and Highlights (Business Wire)
Apr-27-22 06:00AM	Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022 (Business Wire)
Apr-12-22 08:58AM	BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics. (GlobeNewswire) +21.38%
Apr-11-22 06:00AM	Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan (Business Wire) -5.36%
Mar-29-22 06:00AM	Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer (Business Wire)
Mar-19-22 09:19AM	Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher (Simply Wall St.)
Mar-15-22 10:00AM	Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing (Zacks)
Mar-14-22 07:15AM	Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights (Business Wire)
Mar-07-22 04:01PM	Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital (Business Wire)
03:00PM	Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Mar-03-22 06:00AM	Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting (Business Wire) -5.39%
Mar-01-22 06:00AM	Biodesix to Present at Cowens 42nd Annual Healthcare Conference (Business Wire)
Feb-28-22 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022 (Business Wire)
Feb-22-22 06:00AM	Biodesix CEO Scott Hutton Named to The Healthcare Technology Reports List of Top 25 Biotech CEOs in 2022 (Business Wire) -17.03%
Feb-14-22 06:00AM	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited) (Business Wire)
Feb-09-22 06:00AM	Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire) -6.23%
Jan-21-22 09:38PM	Conestoga Capital Advisors, LLC Buys Paycor HCM Inc, Definitive Healthcare Corp, Q2 Holdings ... (GuruFocus.com) -10.14%

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hutton Scott	President & CEO	Feb 12 '24	Sale	1.66	29,708	49,455	465,011	Feb 12 09:45 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 12 '24	Sale	1.66	8,699	14,481	169,410	Feb 12 09:44 PM
O'Kane Kieran	Chief Commercial Officer	Feb 12 '24	Sale	1.66	5,412	9,009	68,005	Feb 12 09:45 PM
Pestano Gary Anthony	Chief Development Officer	Feb 12 '24	Sale	1.66	5,022	8,360	123,250	Feb 12 09:45 PM
Vazquez Chris	Chief Accounting Officer	Feb 12 '24	Sale	1.66	922	1,535	9,548	Feb 12 09:46 PM
Hutton Scott	President & CEO	Feb 09 '24	Sale	1.92	34,682	66,472	494,719	Feb 12 09:45 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 09 '24	Sale	1.92	10,156	19,465	178,109	Feb 12 09:44 PM
O'Kane Kieran	Chief Commercial Officer	Feb 09 '24	Sale	1.92	6,319	12,111	73,417	Feb 12 09:45 PM
Pestano Gary Anthony	Chief Development Officer	Feb 09 '24	Sale	1.92	5,862	11,235	128,272	Feb 12 09:45 PM
Vazquez Chris	Chief Accounting Officer	Feb 09 '24	Sale	1.92	1,077	2,064	10,470	Feb 12 09:46 PM
Hutton Scott	President & CEO	Nov 10 '23	Sale	1.23	1,883	2,308	329,428	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 10 '23	Sale	1.23	491	602	136,573	Nov 13 04:50 PM
O'Kane Kieran	Chief Commercial Officer	Nov 10 '23	Sale	1.23	235	288	47,712	Nov 13 04:50 PM
Pestano Gary Anthony	Chief Development Officer	Nov 10 '23	Sale	1.23	218	267	104,501	Nov 13 04:51 PM
Vazquez Chris	Chief Accounting Officer	Nov 10 '23	Sale	1.23	108	132	6,251	Nov 13 04:51 PM
Hutton Scott	President & CEO	Nov 09 '23	Sale	1.27	1,882	2,391	331,311	Nov 13 04:50 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 09 '23	Sale	1.27	491	624	137,064	Nov 13 04:50 PM
O'Kane Kieran	Chief Commercial Officer	Nov 09 '23	Sale	1.27	234	297	47,947	Nov 13 04:50 PM
Pestano Gary Anthony	Chief Development Officer	Nov 09 '23	Sale	1.27	217	276	104,719	Nov 13 04:51 PM
Vazquez Chris	Chief Accounting Officer	Nov 09 '23	Sale	1.27	107	136	6,359	Nov 13 04:51 PM
SCHULER JACK W	Director	Aug 23 '23	Buy	1.71	87,500	149,240	30,707,722	Aug 23 06:56 PM
SCHULER JACK W	Director	Aug 22 '23	Buy	1.67	8,307	13,859	30,620,222	Aug 23 06:56 PM
SCHULER JACK W	Director	Aug 21 '23	Buy	1.64	32,556	53,411	30,611,915	Aug 23 06:56 PM
Hutton Scott	President & CEO	Aug 10 '23	Sale	1.27	6,889	8,728	318,013	Aug 10 07:28 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 10 '23	Sale	1.27	1,788	2,265	131,535	Aug 10 07:27 PM
O'Kane Kieran	Chief Commercial Officer	Aug 10 '23	Sale	1.27	849	1,076	46,692	Aug 10 07:28 PM
Pestano Gary Anthony	Chief Development Officer	Aug 10 '23	Sale	1.27	786	996	103,558	Aug 10 07:29 PM
Vazquez Chris	Chief Accounting Officer	Aug 10 '23	Sale	1.27	279	353	5,865	Aug 10 07:30 PM
Hutton Scott	President & CEO	Aug 09 '23	Sale	1.39	6,893	9,570	324,902	Aug 10 07:28 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 09 '23	Sale	1.39	1,789	2,484	133,323	Aug 10 07:27 PM
O'Kane Kieran	Chief Commercial Officer	Aug 09 '23	Sale	1.39	850	1,180	47,541	Aug 10 07:28 PM
Pestano Gary Anthony	Chief Development Officer	Aug 09 '23	Sale	1.39	787	1,093	104,344	Aug 10 07:29 PM
Vazquez Chris	Chief Accounting Officer	Aug 09 '23	Sale	1.39	280	389	6,144	Aug 10 07:30 PM
SCHULER JACK W	Director	May 31 '23	Buy	1.35	14,792	20,006	20,589,853	Jun 01 03:00 PM
SCHULER JACK W	Director	May 30 '23	Buy	1.36	11,849	16,150	20,575,061	Jun 01 03:00 PM
SCHULER JACK W	Director	May 25 '23	Buy	1.36	52,508	71,280	20,563,212	May 30 03:03 PM
SCHULER JACK W	Director	May 24 '23	Buy	1.25	35,308	43,980	20,510,704	May 26 03:00 PM
SCHULER JACK W	Director	May 23 '23	Buy	1.15	56,782	65,066	20,475,396	May 25 03:00 PM
SCHULER JACK W	Director	May 22 '23	Buy	1.11	29,425	32,529	20,418,614	May 24 03:47 PM
Hutton Scott	President & CEO	May 10 '23	Sale	1.58	3,848	6,065	240,722	May 10 08:16 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 10 '23	Sale	1.58	973	1,534	117,365	May 10 08:16 PM
Siurek Ryan H	Chief Accounting Officer	May 10 '23	Sale	1.58	564	889	40,268	May 10 08:16 PM
O'Kane Kieran	Chief Commercial Officer	May 10 '23	Sale	1.58	474	747	36,757	May 10 08:16 PM
Pestano Gary Anthony	Chief Development Officer	May 10 '23	Sale	1.58	426	671	99,460	May 10 08:16 PM
Hutton Scott	President & CEO	May 09 '23	Sale	1.57	9,934	15,561	244,570	May 10 08:16 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 09 '23	Sale	1.57	2,512	3,935	118,338	May 10 08:16 PM
Siurek Ryan H	Chief Accounting Officer	May 09 '23	Sale	1.57	1,456	2,281	40,832	May 10 08:16 PM
O'Kane Kieran	Chief Commercial Officer	May 09 '23	Sale	1.57	1,223	1,916	37,231	May 10 08:16 PM
Pestano Gary Anthony	Chief Development Officer	May 09 '23	Sale	1.57	1,101	1,725	99,886	May 10 08:16 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

INBX

Inhibrx Inc

BDSX

Biodesix Inc

Upgrade your FINVIZ experience